RSV is the leading cause of hospitalization in US infants, and in August 2023, the CDC’s vaccine advisory group recommended ...

The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and ...

Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.

Health secretary Robert F. Kennedy Jr.’s decision to discontinue funding of the development of messenger RNA vaccines is not just alarming for the country’s ability to combat future pandemics. It’s ...

For infants born from October to February, maternal vaccination was cost-effective, but compared with vaccination, nirsevimab was cost-effective only in those born in October and November.

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why SNY stock is a strong buy.

The US vaccines market, valued at $29.5B in 2024, is projected to reach $60B by 2033, at a CAGR of 8.2%. Key growth drivers include rising infectious diseases and biotech advancements. Comprehensive ...

HHS Secretary Robert F. Kennedy Jr. last month quietly endorsed recommendations from his handpicked vaccine advisors that everyone in the U.S. ages 6 months and older receive a flu shot for the ...

Continuity Biosciences Appoints Josephine Torrente and Joseph DeSimone, PhD to Board of DirectorsDisclaimer The content, including but not limited to any articles, news, quotes, information, data, ...

The company also records Beyfortus product sales from products supplied to partner Sanofi under the V&I Therapies segment. AstraZeneca’s Key Oncology Drugs Beat Estimates ...